CLEVELAND, April 16, 2012
CLEVELAND, April 16, 2012 /PRNewswire-USNewswire/ -- CardioInsight Technologies Inc., the leading developer of non-invasive electrocardiographic mapping technology, announced today the appointment of Jim Bullock as Chairman of the Company's Board of Directors.
Mr. Bullock is a leader in the cardiac rhythm management field and has served as Chief Executive Officer of Atritech, an electrophysiology company that was acquired by Boston Scientific in 2011, and Endocardial Solutions, a catheter-based cardiac mapping company that was acquired by St. Jude Medical in 2005.
In conjunction with this appointment, CardioInsight has announced that Steve Arless will be leaving his role as Chairman, and Chief Executive Officer. The Board of Directors expresses its appreciation for Mr. Arless' service to the Company during his tenure.
Under Mr. Bullock's direction, Dr. Charu Ramanathan, Co-Founder & Chief Scientific Officer, will function as interim President, and will lead the newly formed Office of the President. Joining Dr. Ramanathan in the Office of the President will be Kevin Mendelsohn, VP of Finance & Corporate Development, and together they will manage the leadership responsibilities of the Company. "The Company is well positioned, and Charu and Kevin are prepared to lead the company through this next phase in its development," said Mr. Bullock. "CardioInsight's noninvasive mapping system has demonstrated the ability to uniquely address clear unmet need in the diagnosis and treatment of patients with cardiac arrhythmias and heart failure, and we look forward to further validating the benefits of this platform in day-to-day clinical practice."
About CardioInsight Technologies Inc.CardioInsight is commercializing a revolutionary technology that non-invasively generates 3D images of the electrical activity of the heart. The images help physicians more accurately treat certain heart ailments such as arrhythmias and congestive heart failure. The Company's ECVUE system non-invasively generates real-time, whole heart images of the electrical activity on the surface of the heart by combining body surface electrical data with 3D anatomical data obtained from imaging scans. It then reconstructs and displays 3D images and other useful measures of cardiac electrical activity as if the measurements were taken directly from the surface of the heart. To date, CardioInsight has completed more than 400 patient studies at leading clinical centers in the United States and Europe, including the Cleveland Clinic Foundation, University Hospitals of Cleveland, Loyola University Medical Center, the University of Pennsylvania Medical Center, and the Hospital Cardiologique Haut Leveque in Bordeaux, France. These studies address a broad variety of cardiac arrhythmias, as well as cardiac resynchronization therapy for congestive heart failure, demonstrating the unique clinical value of the ECVUE system. Results of the studies have been published in leading peer-reviewed journals, and presented at international clinical conferences. The Company has received its CE Mark and markets the ECVUE system in Europe.
For more information, visit CardioInsight's website at www.cardioinsight.com, or contact us at 216-453-5950.
SOURCE CardioInsight Technologies Inc.PR Newswire
Last updated on: 16/04/2012 19:00:06